Peer review reports
From: Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for helicobacter pylori infection in Hainan: a single-center, open-label, noninferiority, randomized controlled trial
| Original Submission |
| 26 Mar 2023 |
Submitted |
Original manuscript
|
| Resubmission - Version 2 |
|
Submitted |
Manuscript version 2
|
| Resubmission - Version 3 |
|
Submitted |
Manuscript version 3
|
| 31 May 2023 |
Reviewed |
Reviewer Report
|
| 10 Jun 2023 |
Reviewed |
Reviewer Report
|
| 29 Jun 2023 |
Author responded |
Author comments - Feihu Bai
|
| Resubmission - Version 4 |
| 29 Jun 2023 |
Submitted |
Manuscript version 4
|
| 29 Jun 2023 |
Author responded |
Author comments - Feihu Bai
|
| Resubmission - Version 5 |
| 29 Jun 2023 |
Submitted |
Manuscript version 5
|
| Publishing |
| 17 Jul 2023 |
Editorially accepted |
|
| 24 Jul 2023 |
Article published |
10.1186/s12876-023-02890-5
|
Learn about peer review
